The trial IMpower150 was conducted to investigate the efficacy of atezolizumab plus bevacizumab plus carboplatin plus paclitaxel (ABCP) versus the standard regimen of bevacizumab plus carboplatin plus paclitaxel (BCP) in chemotherapy-naive patients with non-squamous NSCLC, in which a small number of EGFR-mutant patients had progressed to TKIs. This evidence concerns the gene EGFR and non-small cell lung carcinoma.